Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement